Balyasny Asset Management
LKFT

Balyasny Asset Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Balyasny Asset Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-150,000
Closed -$17M – 1567
2019
Q1 		$17M Buy
+150,000
New +$15.1M 0.11% 258

Other funds holding LKFT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Balyasny Asset Management's LKFT Position: Q4 2022 in Review

Balyasny Asset Management sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2022, closing a stake of 8,147 shares — an estimated $347K sold.

Balyasny Asset Management first reported a position in LKFT in Q4 2020 and held it in 4 quarters. The position peaked at $5.25M in Q1 2021. 75 funds tracked by Wall St. Rank hold LKFT as of Q4 2022.

  • Balyasny Asset Management reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 8,147 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2022, an estimated $347K.
  • Balyasny Asset Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2020 and held it in 4 quarters.
  • Balyasny Asset Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $5.25M in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.